IP Library Granted Patent US 10,932,485
Granted Patent B2
US 10,932,485 · App. 16/515,101 · Granted Mar 2, 2021

Botanical modulator of metabolic disorders

Inventors: Jatinder Rana (Grand Rapids, MI); Kylie Mitchell (Pennington, NJ)
Assignee: Innophos, Inc.
A23L33/135A61K36/185
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,932,485
App. No.
16/515,101
Granted
Mar 2, 2021
Kind
B2
Abstract

Plant-based inhibitors of MMP-9 that also function as PPAR-γ agonists, and the use of such plant-based inhibitors/agonists in modulating metabolic disorders is disclosed. The plant-based inhibitor/agonist is at least an extract obtained from the genus Anacardium.

Claims (14)

1. A composition comprising:

a botanical extract of the testa of the seed of Anacardium occidentale L.,

wherein the botanical extract has been standardized to a catechin content of about 15.0 w/w % or greater, based on total weight of the extract, and

wherein the botanical extract is present in an amount of from about 15.0 μg/mL to about 250.0 μg/mL, and

a carrier,

wherein the composition is effective in modulating one or more metabolic disorders.

2. The composition according to claim 1 , wherein the composition exhibits MMP-9 inhibition.

3. The composition according to claim 1 , wherein the composition further exhibits PPAR-γ agonist activity.

4. The composition according to claim 1 , wherein the composition is a dietary supplement.

5. The composition according to claim 4 , wherein the dietary supplement is in solid dosage form and the carrier is chosen from gelatin, starch, magnesium stearate, talc, gums, silicon dioxide, stearic acid, cellulose and combinations thereof.

6. The composition according to claim 4 , wherein the dietary supplement is in solid dosage form and the carrier is a functional carrier.

7. The composition according to claim 6 , wherein the functional carrier is buckwheat or spelt.

8. The composition according to claim 1 , wherein the composition is effective in reducing the activity of MMP-9.

9. The composition according to claim 1 , wherein the composition is effective as a PPAR-γ agonist.

Assignments (2)
SECURITY INTEREST Recorded Jan 6, 2025
From: INNOPHOS, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT
Reel/Frame 069749/0211 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2021
From: INNOPHOS, INC.
To: INNOPHOS, LLC
Reel/Frame 057925/0188 →
Continuity (2)
Provisional Application 62725448 · Aug 31, 2018
Related Publication 20200068938A1 · Mar 5, 2020